Diagnosis and management of electrolyte emergencies

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 623-651

  Weiss Guillet, Eva Maria ^a   Takala, Jukka ^a   Jakob, Stephan M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Calcium; Hypercalaemia; Hyperkalaemia; Hypermagnesaemia; Hypernatraemia; Hyperphosphataemia; Hypocalcaemia; Hypokalaemia; Hypomagnesaemia; Hyponatraemia; Hypophosphataemia; Magnesium; Phospohorus; Potassium; Sodium

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CHLORIDE; CLODRONIC ACID; DIGITALIS; DIGOXIN; ETACRYNIC ACID; ETIDRONIC ACID; FUROSEMIDE; GALLIUM NITRATE; GLUCONATE CALCIUM; IBANDRONIC ACID; INSULIN; MAGNESIUM; MITHRAMYCIN; PAMIDRONIC ACID; POLYSTYRENESULFONATE SODIUM; POTASSIUM; POTASSIUM BICARBONATE; POTASSIUM CHLORIDE; POTASSIUM DIHYDROGEN PHOSPHATE; SALBUTAMOL; SODIUM; SORBITOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; ZOLEDRONIC ACID; AMILORIDE; AMINOGLYCOSIDE; AMPHOTERICIN B; CISPLATIN; CYCLOSPORIN; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; FOSCARNET; PENICILLIN G; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PSYCHOTROPIC AGENT; SUXAMETHONIUM; TACROLIMUS;

ACID BASE BALANCE; ANAMNESIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONSTIPATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOXICITY; ELECTROLYTE DISTURBANCE; FAMILY; FLUID THERAPY; HEALTH STATUS; HEART DISEASE; HEMODIALYSIS; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTESTINE NECROSIS; INTESTINE PERFORATION; KIDNEY FAILURE; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; POSTOPERATIVE COMPLICATION; POTASSIUM BLOOD LEVEL; PRESCRIPTION; REVIEW; SODIUM BLOOD LEVEL; SUPPLEMENTATION; TISSUE INJURY; TREATMENT PLANNING; URINE OSMOLALITY;

EID: 0344308542     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00056-3     Document Type: Review

References (131)

1. Acher R. Water homeostasis in the living: Molecular organization, osmoregulatory reflexes and evolution. Annales d'Endocrinologie (Paris) 2002; 63: 197-218.
2. Toney GM, Chen QH, Cato MJ & Stocker SD. Central osmotic regulation of sympathetic nerve activity. Acta Physiologica Scandinavica 2003; 177: 43-55.
3. Beltowski J & Wojcicka G. Regulation of renal tubular sodium transport by cardiac natriuretic peptides: Two decades of research. Medical Science Monitor: International Journal of Experimental and Clinical Research 2002; 8: RA39-RA52.
4. Cappuccio FP, Strazzullo P, Giorgione N et al. Renal tubular sodium handling and plasma atrial natriuretic peptide, renin activity and aldosterone in untreated men under normal living conditions. European Journal of Clinical Investigation 1991; 21: 40-46.
5. Kumar S & Berl T. Sodium. Lancet 1998; 352: 220-228.
6. Strange K. Regulation of solute and water balance and cell volume in the central nervous system. Journal of the American Society of Nephrology 1992; 3: 12-27.
7. Trimarchi H, Gonzalez J & Olivero J. Hyponatraemia-associated rhabdomyolysis. Nephron 1999; 82: 274-277.
8. Ayus JC, Varon J & Arieff AI. Hyponatraemia, cerebral oedema, and noncardiogenic pulmonary oedema in marathon runners. Annals of Internal Medicine 2000; 132: 711-714.
9. Androgue HJ & Madias NE. Hyponatraemia. New England Journal of Medicine 2000; 342: 1581-1589.
10. Oster JR & Singer J. Hyponatraemia, hyposmolality, and hypotonicity: Tables and fables. Archives of Internal Medicine 1999; 159: 333-336.
11. Han DS & Cho BS. Therapeutic approach to hyponatraemia. Nephron 2002; 92(supplement I): 9-13.
12. Laureno R & Karp BI. Myelinolysis after correction of hyponatraemia. Annals of Internal Medicine 1997; 126: 57-62.
13. Sterns RH, Cappuccio JD, Silver SM & Cohen EP. Neurologic sequelae after treatment of severe hyponatraemia: A multicenter perspective. Journal of the American Society of Nephrology 1994; 4: 1522-1530.
14. Karp BI & Laureno R. Pontine and extrapontine myelinolysis: A neurologic disorder following rapid correction of hyponatraemia. Medicine (Baltimore) 1993; 72: 359-373.
15. Oh MS, Kim HJ & Carroll HJ. Recommendations for treatment of symptomatic hyponatraemia. Nephron 1995; 70: 143-150.
16. Menger H & Jorg J. Outcome of central pontine and extrapontine myelinolysis (n = 44). Journal of Neurology 1999; 246: 700-705.
17. Menger H, Mackowski J, Jorg J & Cramer BM. Pontine and extra-pontine myelinolysis. Early diagnostic and prognostic value of cerebral CT and MRI. Der Nervenarzt 1998; 69: 1083-1090.
18. Berl T. Treating hyponatraemia: Damned if we do and damned if we don't. Kidney International 1990; 37: 1006-1018.
19. Adrogue HJ & Madias NE. Aiding fluid prescription for the dysnatremias. Intensive Care Medicine 1997; 23: 309-316.
20. Adrogue HJ & Madias NE. Hypernatraemia. New England Journal of Medicine 2000; 342: 1493-1499.
21. McManus ML, Churchwell KB & Strange K. Regulation of cell volume in health and disease. New England Journal of Medicine 1995; 333: 1260-1266.
22. Kang SK, Kim W & Oh MS. Pathogenesis and treatment of hypernatraemia. Nephron 2002; 92(supplement I): 14-17.
23. Palevsky PM. Hypernatraemia. In Greenberg A (ed.) Primer on Kidney Diseases. San Diego: Academic Press, 1998, pp 64-71.
24. Clausen T & Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney International 1989; 35: 1-13.
25. Halperin ML & Kamel KS. Potassium. Lancet 1998; 352: 135-140.
26. Field MJ & Giebisch GJ. Hormonal control of renal potassium excretion. Kidney International 1985; 27: 379-387.
27. Giebisch G. Renal potassium transport: Mechanisms and regulation. American Journal of Physiology 1998; 274: F817-F833.
28. Cohn JN, Kowey PR, Whelton PK & Prisant LM. New guidelines for potassium replacement in clinical practice: A contemporary review by the National Council on Potassium in Clinical Practice. Archives of Internal Medicine 2000; 160: 2429-2436.
29. Kim GH & Han JS. Therapeutic approach to hypokalemia. Nephron 2002; 92(supplemen I): 28-32.
30. Gennari FJ. Hypokalemia. New England Journal of Medicine 1998; 339: 451-458.
31. Schulman M & Narins RG. Hypokalemia and cardiovascular disease. American Journal of Cardiology 1990; 65: 4E-9E.
32. Wahr JA, Parks R, Boisvert D et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter study of Perioperative Ischemia Research Group. JAMA 1999; 281: 2203-2210.
33. Stedwell RE, Allen KM & Binder LS. Hypokalaemic paralyses: A review of the etiologies, pathophysiology, presentation, and therapy. American Journal of Emergency Medicine 1992; 10: 143-148.
34. Sterns RH, Cox M, Feig PU & Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 1981; 60: 339-354.
35. Adrogue HJ, Lederer ED, Suki WN & Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65: 163-172.
36. Sopko JA & Freeman RM. Salt substitutes as a source of potassium. JAMA 1977; 238: 608-610.
37. Charytan D & Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Archives of Internal Medicine 2000; 160: 1605-1611.
38. Rose BD & Post TW. Clinical Physiology of Acid Base and Electrolyte Disorders, 5th edn. New York: McGraw-Hill, 2001.
39. Kim HJ & Han SW. Therapeutic approach to hyperkalemia. Nephron 2002; 92(supplement I): 33-40.
40. Perazella MA. Drug-induced hyperkalaemia: Old culprits and new offenders. American Journal of Medicine 2000; 109: 307-314.
41. Weiner ID & Wingo CS. Hyperkalemia: A potential silent killer. Journal of the American Society of Nephrology 1998; 9: 1535-1543.
42. Martinez-Vea A, Bardaji A, Garcia C & Oliver JA. Severe hyperkalemia with minimal electrocardiographic manifestations: A report of seven cases. Journal of Electrocardiology 1999; 32: 45-49.
43. Greenberg A. Hyperkalemia: Treatment options. Seminars in Nephrology 1998; 18: 46-57.
44. Allon M & Copkney C. Albuterol and insulin for treatment of hyperkalaemia in hemodialysis patients. Kidney International 1990; 38: 869-872.
45. Allon M, Dunlay R & Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Annals of Internal Medicine 1989; 110: 426-429.
46. Allon M & Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: Interactions with insulin and albuterol. American Journal of Kidney Disease 1996; 28: 508-514.
47. Nolph KD, Popovich RP, Ghods AJ & Twardowski Z. Determinants of low clearances of small solutes during peritoneal dialysis. Kidney International 1978; 13: 117-123.
48. Blumberg A, Weidman P, Shaw S & Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. American Journal of Medicine 1988; 85: 507-512.
49. Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. American Journal of Medicine 1999; 106: 238-253.
50. Bushinsky DA & Monk RD. Electrolyte quintet: Calcium. Lancet 1998; 352: 306-311.
51. Broadus AE. Mineral balance and homeostasis. In Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelpia: Lippincott/Raven, 1996, pp 57-63.
52. Graber ML. Magnesium deficiency: Pathophysiologic and clinical overview. American Journal of Kidney Disease 1995; 25: 973.
53. Tohme JF & Bilezikian JP. Hypocalcemic emergencies. Endocrinology & Metabolism Clinics of North America 1993; 22: 363-375.
54. Sheldon RS, Becker WJ, Hanley DA & Culver RL. Hypoparathyroidism and pseudotumor cerebri: An infrequent clinical association. Canadian Journal of Neurological Science 1987; 14: 622-625.
55. Bashour T, Basha HS & Cheng TO. Hypocalcemic cardiomyopathy. Chest 1980; 78: 663-665.
56. Sutton RAL & Dirks JH. Disturbances of calcium and magnesium metabolism. In Brenner BM & Rector FC (eds) The Kidney. Philadelphia: Saunders, 1996, pp 1038-1085.
57. Heath III H. Clinical spectrum of primary hyperparathyroidism: Evolution with changes in medical practice and technology. Journal of Bone & Mineral Research 1991; 6(supplement 2): S63-S70.
58. Gardner Jr. EC & Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. Southern Medical Journal 1981; 74: 197-199.
59. Carnaille B, Oudar C, Pattou F et al. Pancreatitis and primary hyperparathyroidism: Forty cases. Australian & New Zealand Journal of Surgery 1998; 68: 117-119.
60. Caruana RJ & Buckalew Jr VM. The syndrome of distal (type I) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltimore) 1988; 67: 84-99.
61. Campese VM. Calcium, parathyroid hormone, and blood pressure. American Journal of Hypertension 1989; 2: 34S-44S.
62. Petersen P. Psychiatric disorders in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1968; 28: 1491-1495.
63. Rosenqvist M, Nordenstrom J, Andersson M & Edhag OK. Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism. Clinical Endocrinology (Oxford) 1992; 37: 29-33.
64. Casez J, Pfammatter R, Nguyen Q, et al. Diagnostic approach to hypercalcemia: Relevance of parathyroid hormone and parathyroid hormone-related protein measurements. European Journal of Internal Medicine 2001; 12(4): 344-349.
65. Lafferty FW. Differential diagnosis of hypercalcaemia. Journal of Bone & Mineral Research 1991; 6(supplement 2): S51-S59.
66. Beall DP & Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcaemia. Medicine (Baltimore) 1995; 74: 89-96.
67. Esbrit P. Hypercalcaemia of malignancy - New insights into an old syndrome. Clinical Laboratory 2001; 47: 67-71.
68. Strewler GJ. The physiology of parathyroid hormone-related protein. New England Journal of Medicine 2000; 342: 177-185.
69. Sharma OP. Hypercalcaemia in granulomatous disorders: A clinical review. Current Opinion in Pulmonary Medicine 2000; 6: 442-447.
70. Seymour JF & Gagel RF. Calcitriol: The major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82: 1383-1394.
71. Fukugawa M & Kurokawa K. Calcium homeostasis and imbalance. Nephron 2002; 92(supplement 1): 41-45.
72. Van Dijk JM, Sonnenblick M, Weissberg N & Rosin A. Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma. Israel Journal of Medical Science 1986; 22: 143-144.
73. Schipani E, Langman CB, Parfitt AM et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. New England Journal of Medicine 1996; 335: 708-714.
74. Saarela T, Simila S & Koivisto M. Hypercalcaemia and nephrocalcinosis in patients with congenital lactase deficiency. Journal of Pediatrics 1995; 127: 920-923.
75. Body JJ. Current and future directions in medical therapy: Hypercalcemia. Cancer 2000; 88(supplement): 3054-3058.
76. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Seminars in Oncology 2001; 28(4 supplement 11): 49-53.
77. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in Oncology 2002; 29(6 supplement 21): 12-18.
78. Leyland-Jones B. Treatment of cancer-related hypercalcaemia: The role of gallium nitrate. Seminars in Oncology 2003; 30(2 supplement 5): 13-19.
79. Wisneski LA. Salmon calcitonin in the acute management of hypercalcaemia. Calcified Tissue International 1990; 46(supplement): S26-S30.
80. Gardner DG. Hypercalcemia and sarcoidosis - Another piece of the puzzle falls into place. American Journal of Medicine 2001; 110: 736-737.
81. Urena P & Frazao JM. Calcimimetic agents: Review and perspectives. Kidney International 2003; 85(supplement): 91-96.
82. Sezer O, Heider U, Zavrski I et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098.
83. Yu J, Papavasiliou V, Rhim J et al. Vitamin D analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995; 6: 101-108.
84. Weisinger JR & Bellorin-Font E. Magnesium and phosphorus. Lancet 1998; 352: 391-396.
85. White RE & Hartzell HC. Magnesium ions in cardiac function. Regulator of ion channels and second messengers. Biochemical Pharmacology 1989; 38: 859-867.
86. De Rouffignac C & Quamme G. Renal magnesium handling and its hormonal control. Physiological Reviews 1994; 74: 305-322.
87. Quamme GA. Control of magnesium transport in the thick ascending limb. American Journal of Physiology 1989; 256: F197-F210.
88. Quamme GA. Renal magnesium handling: New insights in understanding old problems. Kidney International 1997; 52: 1180-1195.
89. Whang R, Whang DD & Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Archives of Internal Medicine 1992; 152: 40-45.
90. England MR, Gordon G, Salem M & Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268: 2395-2402.
91. Kafka H, Langevin L & Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Archives of Internal Medicine 1987; 147: 465-469.
92. Al Ghamdi SM, Cameron EC & Sutton RA. Magnesium deficiency: Pathophysiologic and clinical overview. American Journal of Kidney Disease 1994; 24: 737-752.
93. Elisaf M, Panteli K, Theodorou J & Siamopoulos KC. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnesium Research 1997; 10: 315-320.
94. Morisaki H, Yamamoto S, Morita Y et al. Hypermagnesemia-induced cardiopulmonary arrest before induction of anesthesia for emergency cesarean section. Journal of Clinical Anesthesia 2000; 12: 224-226.
95. Schelling JR. Fatal hypermagnesemia. Clinical Nephrology 2000; 53: 61-65.
96. Danisi G & Murer H. Inorganic phosphate absorption in the small intestine. In Field M & Fritzel RA (eds) Handbook of Physiology. Bethesda: MD: American Physiology Society, 1991, pp 323-336.
97. Wesson LG. Homeostasis of phosphate revisited. Nephron 1997; 77: 249-266.
98. Subramanian R & Khardori R. Severe hypophosphatemia - Pathophysiologic implications, clinical presentations, and treatment. Medicine 2000; 79: 1-8.
99. Murer H, Markovich D & Biber J. Renal and small-intestinal sodium-dependent symporters of phosphate and sulfate. Journal of Experimental Biology 1994; 196: 167-181.
100. Murer H. Cellular mechanisms in proximal tubular P(I) reabsorption - Some answers and more questions. Journal of the American Society of Nephrology 1992; 2: 1649-1665.
101. Murer H & Biber J. Cellular mechanisms in renal tubular transport of divalent inorganic anions. Nephrologie 1996; 17: 365-369.
102. Shiber GR & Mattu A. Serum phosphate abnormalities in the emergency department. The Journal of Emergency Medicine 2002; 23(4): 395-400.
103. Knochel JP & Agarwal R. Hypophosphatemia and hyperphosphatemia. In Brenner BM (ed.) Brenner and Rector's the Kidney. Philadelphia: WB Saunders, 1996, pp 1086-1133.
104. Knochel JP. Hypophosphatemia in the alcoholic. Archives of Internal Medicine 1980; 140: 613-615.
105. Lotz M, Zisman E & Bartter FC. Evidence for a phosphorus-depletion syndrome in man. New England Journal of Medicine 1968; 278: 409-415.
106. Lennquist S, Lindell B, Nordstrom H & Sjoberg HE. Hypophosphatemia in severe burns - Prospective study. Acta Chirurgica Scandinavica 1979; 145: 1-6.
107. George R & Shiu MH. Hypophosphatemia after major hepatic resection. Surgery 1992; 111: 281-286.
108. Goldstein J, Vincent JL, Leclerc JL et al. Hypophosphatemia after cardiothoracic surgery. Intensive Care Medicine 1985; 11: 144-148.
109. Halevy J & Bulvik S. Severe hypophosphatemia in hospitalized patients. Archives of Internal Medicine 1988; 148: 153-155.
110. Fuller TJ, Carter NW, Barcenas C & Knochel JP. Reversible myopathy associated with phosphorus (P) depletion. Clinical Research 1975; 23: A535.
111. Benesch R & Benesch RE. Effect of organic phosphates from human erythrocyte on allosteric properties of hemoglobin. Biochemical and Biophysical Research Communications 1967; 26: 162.
112. Travis SF, Sugerman HJ, Ruberg RL et al. Alterations of red-cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatemia in patients receiving intravenous hyperalimentation. New England Journal of Medicine 1971; 285: 763-768.
113. Oconnor LR, Wheeler WS & Bethune JE. Effect of hypophosphatemia on myocardial performance in man. New England Journal of Medicine 1977; 297: 901-903.
114. Aubier M, Murciano D, Lecocguic Y et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. New England Journal of Medicine 1985; 313: 420-424.
115. Knochel JP. Hypophosphatemia and rhabdomyolysis. American Journal of Medicine 1992; 92: 455-457.
116. Klock JC, Williams HE & Mentzer WC. Hemolytic anemia and somatic-cell dysfunction in severe hypophosphatemia. Archives of Internal Medicine 1974; 134: 360-364.
117. Craddock PR, Yawata T et al. Acquired phagocyte dysfunction resulting from parenteral hyperalimentation. New England Journal of Medicine 1974; 290: 1403-1407.
118. Yawata Y, Hebbel RP, Silvis S et al. Blood-cell abnormalities complicating hypophosphatemia of hyperalimentation - Erythrocyte and platelet ATP deficiency associated with hemolytic anemia and bleeding in hyperalimented dogs. Journal of Laboratory and Clinical Medicine 1974; 84: 643-653.
119. Larner AJ. Pseudohyperphosphatemia. Clinical Biochemistry 1995; 28: 391-393.
120. Boivin MA & Kahn SR. Symptomatic hypocalcaemia from oral sodium phosphate: A report of two cases. American Journal of Gastroenterology 1998; 93: 2577-2579.
121. Sutters M, Gaboury CL & Bennett WM. Severe hyperphosphatemia and hypocalcemia: A dilemma in patient management. Journal of the American Society of Nephrology 1996; 7: 2056-2061.
122. Yamaguchi T, Sugimoto T, Imai Y et al. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone 1995; 16(supplement 4): 247S-250S.
123. Uhlig K, Sarnak MJ & Singh AK. New approaches to the treatment of calcium and phosphorus abnormalities in patients on hemodialysis. Current Opinion in Nephrology & Hypertension 2001; 10: 793-798.
124. Hillier TA, Abbott RD & Barett EJ. Hyponatraemia: Evaluating the correction factor for hyperglycemia. American Journal of Medicine 1999; 106: 399-403.
125. Gerbes AL, Gulberg V, Gines P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-939.
126. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696.
127. Verbalis JG. Vasopressin V2 receptor antagonists. Journal of Molecular Endocrinology 2002; 29: 1-9.
128. Sterns RH. Hypernatremia in the intensive care unit: Instant quality - Just add water. Critical Care Medicine 1999; 27: 1041-1042.
129. Kruse JA & Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Archives of Internal Medicine 1990; 150: 613-617.
130. Wingo CSWID, Disorders of potassium balance. In Brenner BM (ed.) The Kidney. Philadelphia: Saunders, 2000, pp 998-1035.
131. Rashid A & Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: An underrecognized condition. The American Journal of Surgical Pathology 1997; 21: 60-69.